WO2005072707A1 - ナノ粒子含有組成物およびその製造方法 - Google Patents
ナノ粒子含有組成物およびその製造方法 Download PDFInfo
- Publication number
- WO2005072707A1 WO2005072707A1 PCT/JP2005/000952 JP2005000952W WO2005072707A1 WO 2005072707 A1 WO2005072707 A1 WO 2005072707A1 JP 2005000952 W JP2005000952 W JP 2005000952W WO 2005072707 A1 WO2005072707 A1 WO 2005072707A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanoparticle
- producing
- skin
- containing composition
- vitamin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8129—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Definitions
- Nanoparticle-containing composition and method for producing the same
- the present invention relates to a nanoparticle-containing composition in which primary particles including nanoparticles are formed, and the primary particles are combined so that the primary particles are reversibly assembled.
- a nanoparticle-containing composition suitable for application to the skin.
- vitamin C acts on the deep skin to restore damage.
- vitamin C acts on melanocytes (pigment cells) deep in the skin to produce a whitening effect, and also acts on dermal fibroblasts to produce collagen.
- vitamin C improves lipid metabolism in deep skin adipocytes (adipocytes) involved in cellulite.
- vitamin preparations such as vitamin C hardly penetrate deep into the skin by merely topical application to the skin surface. Therefore, as a method of promoting penetration into the deep part of the skin, a method of permeating while applying an electric current (about 0.4 mA) with an iontophoresis device, a method of permeating while applying ultrasonic waves with an ultrasonic beauty device, or a method using goggles IPL (instantaneous strobe light) photofacial and other methods that penetrate while receiving IPL irradiation are used.
- an electric current about 0.4 mA
- IPL instantaneous strobe light
- pumice-like alumina is used to exfoliate the degraded stratum corneum and exfoliate the stratum corneum, and the impregnated oily vitamin C It is also known to hit (ZE) deep into the skin.
- Patent Document 1 describes a method for producing an emulsion capable of improving permeability into skin and hair.
- Patent Literature 2 describes that a vitamin preparation (active agent) is applied to the skin after being captured by microparticles (such as nanospheres) of a biodegradable polymer of 11 lOOOnm.
- Patent Document 3 discloses a method for stably producing nanoparticles containing an active ingredient
- Patent Document 4 discloses a nanosphere force having excellent stability and non-stickiness. Cosmetics containing fine particles having good slip properties are described.
- Patent Document 6 as a method for producing Nanosufuea, poly Bulle alcohol 0.5 wt 0/0 - 20 wt 0/0 including organic solvent by adding a biodegradable polymer, a drug contained The ability to prevent the initial release of S is described.
- Patent Document 7 discloses a method for producing nanocomposite particles in which nanoparticles containing a drug are complexed. By combining the nanoparticles with this method, the nanoparticles are collected into easy-to-handle agglomerates before use, and they return to the nanoparticles when exposed to moisture during use and have properties such as high reactivity. healing nanocomposite particles are created. This solves the above problem.
- the nanocomposite particles of Patent Document 7 are mainly intended for oral preparations and transpulmonary preparations, and further improvement is required when applied to the skin. Specifically, first, since it is applied directly to the skin, the feeling of use is important. Therefore, it is necessary to consider how to improve the usability.
- nanocomposite particles When the nanocomposite particles are externally applied to the skin as a cosmetic or dermatological agent, they may be mixed with a liquid such as an emulsion. Since nanocomposite particles must be stored in a dry state until just before use due to their properties, when a mixed solution with the above-mentioned emulsion is commercialized, it is mixed with the emulsion immediately before use. In this case, it is considered to be an effective means, for example, to fill single-use containers into small containers and sell them. At this time, nanocomposite particles having high bulk density, which have excellent fluidity, can be easily filled in a small container, and can be more frequently filled in a small container, are required.
- Patent Document 1 Japanese Patent Application Laid-Open No. 7-165530 (Publication date: June 27, 1995)
- Patent Document 2 Patent No. 3001821 (Registration date: November 12, 1999)
- Patent Document 3 Japanese Patent Publication No. 2001-510790 (Published date: August 7, 2001)
- Patent Document 4 Japanese Patent Application Laid-Open No. 2000-178129 (Publication date: June 27, 2000)
- Patent Document 5 Japanese Patent Application Laid-Open No. 2003-073233 (Published date: March 12, 2003)
- Patent Document 6 JP-A-9-1110678 (Published on April 28, 1997)
- Patent Document 7 Japanese Patent Application Laid-Open No. 2003-275281 (Published: September 30, 2003)
- Patent Document 8 Patent No. 2720247 (Registration date: November 21, 1997)
- Non-Patent Document 1 Kunika Akagi, Kikuko Yoshimitsu, Haruko Mimura, Nobuko Miwa, "Chapter 28 Evaluation Method of Drug Penetration Using Human Extracted Skin”, edited by Shinhiwa Miwa, “Beautiful Skin Protection and Biotechnology ”, 1st edition, CMC Publishing Co., Ltd., August 31, 2003, p.301-304
- the present invention has been made in view of the above-mentioned problems, and an object of the present invention is to provide a nanopowder containing composited nanoparticle, which can be easily and densely packed into a container having a good feeling of use. An object of the present invention is to realize a method for efficiently producing a particle-containing composition.
- a method for producing a nanoparticle-containing composition is a method for producing drug-containing composite particles containing a drug and a biocompatible polymer, wherein polyvinyl alcohol is used in an amount of 0.1%.
- the method is characterized by comprising a distilling step of distilling the organic solvent from the containing solution and a complexing step of complexing the nanoparticles.
- the concentration of the polyvinyl alcohol is 0.2% by weight or less.
- the present invention provides the method for producing a nanoparticle-containing composition having the above configuration, wherein the nanoparticle is used.
- the particle size of the particles was 50 nm or more and 250 nm or less.
- water is added to the nanoparticle-containing solution for a predetermined period from at least the beginning of the distillation step.
- the drug is a vitamin or a vitamin derivative.
- a vitamin or a vitamin derivative is complexed together with the nanoparticles in the complexing step.
- the sugar alcohol is complexed with the nanoparticles in the complexing step.
- the complexing step is performed by freeze-drying.
- the present invention is a cosmetic containing the nanoparticle-containing composition produced by the method for producing a nanoparticle-containing composition having the above-described configuration.
- the present invention is also a transdermal drug containing a nanoparticle-containing composition produced by the method for producing a nanoparticle-containing composition having the above-described configuration.
- the present invention is a nanoparticle-containing composition including nanocomposite particles in which nanoparticles containing vitamins or vitamin derivatives and water-soluble vitamins or vitamin derivatives are complexed.
- FIG. 1 is a drawing showing steps of a method for producing a nanoparticle-containing composition according to an embodiment of the present invention.
- FIG. 2 is a schematic diagram illustrating a spherical crystallization method used in a method for producing a drug-containing composite particle according to one embodiment of the present invention.
- FIG. 2 (a) shows a granulation process of the spherical granulation method.
- FIG. 2 (b) is a diagram showing a granulation process in the emulsion solvent diffusion method.
- FIG. 3 is a drawing showing a container of the composition containing nanoparticles according to the embodiment of the present invention.
- FIG. 4 is a drawing showing a structure of a nanoparticle-containing composition according to an embodiment of the present invention.
- Garden 5 Drawings showing the experimental results of measuring the penetration of the nanoparticle-containing composition into the skin according to the embodiment of the present invention into the skin.
- FIG. 5 (a) is a comparative example, and FIG. 5 (b) is an example.
- FIG. 5 (c) is an enlarged view showing a part of FIG. 5 (b).
- FIG. 8 is a drawing showing the experimental results of measuring the ultraviolet protection effect of the nanoparticle-containing composition according to the embodiment of the present invention.
- FIG. 8 (a) is a comparative example
- FIG. 8 (b) is an example
- FIG. 8 (c) is a drawing showing a case where no ultraviolet light was irradiated in the example.
- the method for producing the drug-containing composite particles according to the present embodiment is a method of forming primary particles including nanoparticles, and further combining the primary particles so that the primary particles are reversibly assembled. is there.
- the method for producing drug-containing composite particles according to the present invention is suitably used in a wide range of fields such as the development of various new materials.
- the method is preferably used for producing powder as a material for cosmetics. Can be. This is because when the composite particles are used, they pass through the primary particles, are dispersed in nanoparticle units, penetrate deep into the skin, and gradually from the nanoparticles at the deep skin Is to release the drug.
- the material of the nanoparticles in the present invention is not particularly limited as long as it can be converted into nanoparticles.
- the method for producing the nanoparticles is not particularly limited as long as the method can process the target substance into particles having an average particle size of less than 100 nm. When forming particles, it is very preferable to use a spherical crystallization method.
- the spherical crystallization method is a method in which spherical crystal particles are designed by controlling the crystal formation / growth process in the final process of compound synthesis, and the physical properties thereof can be directly controlled to be processed.
- Spherical crystallization can be divided into spherical granulation (SA method) and emulsion diffusion method (ESD method) depending on the mechanism of formation and aggregation of crystals to be crystallized.
- the SA method is a method of forming spherical granulated crystals by using two types of solvents to precipitate drug crystals. Specifically, first, a poor solvent that hardly dissolves the target drug and a good solvent that can dissolve the drug well and can be mixed and diffused in the poor solvent are prepared. Then, the drug solution dissolved in the good solvent is dropped into the poor solvent with stirring. At this time, as shown in the leftmost diagram of FIG. 2 (a), the drug crystals 51 are precipitated in the system by utilizing the transfer of the good solvent to the poor solvent and the decrease in solubility due to the temperature effect and the like.
- liquid liquid cross-linking agent
- the liquid Agent 52 is released. Then, a bridge is formed between the crystals 51, and the crystals 51 start to aggregate non-randomly due to the interfacial tension and the capillary force, as shown in the second diagram from the left in FIG. 2A. This state is referred to as a fan state.
- the type of the good solvent and the poor solvent, and the type of the liquid cross-linking agent 52 depend on the target drug. It is determined according to the type of the object, and is not particularly limited. The conditions at the time of crystal precipitation and the method of applying the mechanical shearing force are not particularly limited, either. The type depends on the kind of the target drug, the particle size of the spherical granulated crystal 54 (nano order in the present invention), and the like. May be determined as appropriate.
- the ESD method Unlike the force SA method, which uses two types of solvents, the ESD method also forms an emulsion and then crystallizes the drug in a spherical shape using the mutual diffusion between a good solvent and a poor solvent. Is the way. Specifically, first, a drug solution dissolved in a good solvent is dropped into a poor solvent with stirring. At this time, since the drug and the good solvent have an affinity, the transfer of the good solvent to the poor solvent is delayed, and an emulsion droplet 55 is formed as shown in the left diagram of FIG. 2 (b).
- the types of the good solvent and the poor solvent are also determined according to the type of the target drug and the like, and are not particularly limited, as in the SA method.
- the conditions for forming the emulsion and the cooling conditions for crystal precipitation are not particularly limited, either.
- nanoparticles can be formed by a physicochemical method, and the obtained nanoparticles are substantially spherical. Can be easily formed as necessary.
- the nanoparticles When nanoparticles are applied to a living body, the nanoparticles may be modified with a biocompatible polymer or the like, but the spherical crystallization method only dissolves the drug and the biocompatible polymer in a good solvent. It is very preferred because both can form composite nanoparticles.
- the biocompatible polymer as a material constituting the biocompatible nanoparticles obtainable by the above-mentioned spherical crystallization method is biocompatible with low irritation to the living body and has low toxicity.
- a biodegradable substance that is metabolized is desirable.
- the medicine that is contained is contained Preferably, the particles are emitting particles.
- examples of such a material include polylactic acid * glycolic acid copolymer (PLGA). It is known that PLGA can contain a drug and can be stored for a long period of time while maintaining the efficacy of the drug. Furthermore, due to the PLGA hydrolysis-long half-life characteristics, sustained release from several days to one month may be possible.
- Other examples of the biocompatible polymer include polyglycolic acid (PGA) and polylactic acid (PLA). In addition, these copolymers may have a charged group such as an amino acid or a group capable of becoming a functional group.
- Biocompatible polymers other than the above include polyamides, polycarbonates, polyalkylenes such as polyethylene, polypropylene, polyethylene glycol, polyethylene oxide, polyethylene terephthalate, polybutyl alcohol, polybutyl ether and polybutyl ester.
- polybutyl compounds polymers of atalinoleic acid and methacryloleic acid, cellulose and other polysaccharides, and peptides or proteins, or copolymers or mixtures thereof.
- polylactic acid * glycolic acid is particularly preferably used as the biocompatible polymer.
- the molecular weight of the polylactic acid 'greenoleic acid is preferably in the range of 5,000-200,000, more preferably in the range of 15,000-25,000.
- the composition ratio of lactic acid and glycolic acid may be 1: 99-99: 1, but it is preferable that the ratio of lactic acid to glycolic acid is 0.333 to 1.
- the PLGA having a content of lactic acid and dalicholate in the range of 25% by weight to 65% by weight is amorphous and is soluble in an organic solvent such as acetone, so that it is preferably used. .
- Examples of drugs included in the biocompatible nanoparticles include vitamins, provitamins (vitamin derivatives), and various drugs.
- the nanoparticle-containing composition of the present invention has excellent penetration from the skin and can be suitably used as a cosmetic or transdermal drug.
- the production of PLGA encapsulating provitamin as the biocompatible nanoparticle can provide a provitamin-containing cosmetic that works efficiently.
- Examples of the provitamin encapsulated in the nanoparticles include derivatives of vitamins A, B, C, and E. Specifically, VC-IP (liposoluble ascorbyl tetrahexynoledecanoate) and VE (tokof acetate) Erol), VA (vitamin ⁇ retinol, vitamin ⁇ precursor: -carotene).
- the encapsulation rate in these nanoparticles was 15% for VC-IP and 20% for VE when the solvent-diffusion method in water of the spherical crystallization method was used.
- provitamin C (such as VC-IP) is preferably used as a drug to be encapsulated in nanoparticles because its effect is improved by being supplied to the deep part of the skin.
- Pro-vitamin C needs to be provided deep into the skin only if the deep skin is damaged by ultraviolet A-waves (UVA), sebum oxidation, and microbes. Is to be restored.
- UVA ultraviolet A-waves
- vitamin C acts on melanocytes (pigment cells) deep in the skin to produce a whitening effect, and acts on dermal fibroblasts to produce collagen.
- vitamin C improves lipid metabolism in skin epidermis and deep adipocytes (adipocytes) involved in cellulite.
- VC-IP of oil-based provitamin C is expected to have an effect of preventing DNA chain breakage of human keratinocyte HaCaT by UVA, and a protective effect of skin cell DNA chain breakage by ultraviolet B wave (UVB).
- transdermal drug examples include fentanyl quenate as an anesthetic, bifonazole as a drug for parasitic skin diseases (eg, athlete's foot), minoxidinole as a hair restorer, and the like.
- insulin a drug for diabetes
- calcitonin a drug for osteoporosis
- the encapsulation rate was 6-10% for insulin and 6-10% for calcitonin.
- the particle size of the nanoparticles may be 1, OOOnm or less, but is preferably 250nm or less. In general, it is considered that the size of skin cells is 15, OOOnm, and the skin cell spacing is about 70nm, which varies between shallow and deep areas of the skin. This is preferable because the nanoparticles have extremely high permeability to the skin.
- nanoparticles as small as possible and having a size of 50 nm or more, penetration into cell intervals can be expected without phagocytosis of cells.
- the nanoparticles obtained as described above can be re-dispersed into aggregated particles when powdered by freeze-drying or the like (composite can be formed).
- the compressive force is obtained by a fluidized bed dry granulation method or a dry mechanical particle compounding method (for example, by using an apparatus described in Patent Document 7; specifically, by a Mekanov Fusion System AMS (manufactured by Hosokawa Micron Corporation)). And even if it is compounded by increasing the shearing force, it can be integrated again in a separable state. As a result, the nanoparticles become easy-to-handle aggregated particles in which the nanoparticles are collected before use, and the nanocomposite particles which return to the nanoparticles and restore the properties such as high reactivity by touching moisture during use can be obtained.
- the biocompatible nanoparticles are recombined with an organic or inorganic substance so that they can be redispersed.
- sugar alcohols include mannitol, trehalose, sorbitol, erythritol, maltose, xylitol, and the like. Of these, mannitol is particularly preferred. Mannitol is chemically stable, non-oxidizing, moisture resistant and suitable for carrier particles. In particular, trehalose is very suitable because it enhances the whitening effect when used in combination with a whitening agent such as vitamin C or a derivative thereof (see Patent Document 8).
- skin affinity may be increased by complexing chitosan, which enhances mucosal adhesion, or complexing a phospholipid (lecithin / phosphadylcholine) on the surface of the nanoparticles.
- complexing polyethylene glycol (PEG) makes it easier to dissolve in water and enhances skin permeability.
- PEG polyethylene glycol
- a drug such as provitamin
- the skin is separated from the contained drug that is gradually released from the nanoparticle.
- a fast-acting drug that dissolves from the surface of the composite particles can be acted on.
- examples of such drugs include water-soluble provitamins such as VC-PMG (water-soluble ascorbyl phosphate Mg), AA2G (ascorbic acid darcoside), panthenol (water-soluble vitamin B), and L-cysteine. No. With this configuration, PLGA composite
- the drug is water-soluble, it will dissolve quickly and show a fast-acting effect.
- the drug has both a rapid effect and a slow effect, so that it can be penetrated for a long period after application to the skin.
- the composite particles produced in this way have an effect of penetrating into the skin even if they are adhered to the skin as they are and transporting the contained or adhered drug to the deep part of the skin. Produces more effective permeability.
- PLGA is mixed with water, it is hydrolyzed, causing the composite particles to lose their ability to transport in a short period of time. Therefore, when using as such an emulsion, the emulsion and the powder are filled and stored in separate containers adjacent to each other as shown in Fig. 3, and the containers are separated immediately before use. It is preferable to use a container that can mix the emulsion and the powder.
- a 0.2% by weight aqueous solution obtained by diluting 8 g of polyvinyl alcohol (PVA) with 4000 ml of water is added to the vigor.
- PVA aqueous solution was stirred at 40 ° C. and 400 rpm, and 80 g of polylactic glycolic acid (PLGA: PLGA7520 manufactured by Wako Pure Chemical), acetone 1 600 ml, ethanolanol 800 ml, and provitamin C were stirred in the PVA aqueous solution.
- a solution comprising 12 g of fat-soluble tetrahexyldecanoate corvinole (VC-IP: manufactured by Nikko Chemical) was added dropwise at a rate of 15 ml / min. This produced a nanoparticle-containing solution.
- the organic solvent was distilled off while stirring at 40 ° C. and 100-200 rpm while adding purified water (4 ml / min, total 320 ml) to the nanoparticle-containing solution.
- PLGA composite particles were obtained.
- the obtained PLGA composite particles are obtained by integrating the powder side container and the solution side container shown in Fig.
- a powder side container (capacity: 1.5 cc), which is a business-use dispersion type container that can be mixed at the time of use. 160 mg was charged, and the solution side container (capacity: 5.5 cc) was filled with emulsion. As a result, an emulsion containing the PLGA composite particles is obtained by mixing just before use.
- the PVA concentration in the mixing step is less than 0.5% by weight, preferably 0.4% by weight or less, more preferably 0.2% by weight. It is preferred that: The content is more preferably 0.1% by weight or more, and more preferably 0.2% by weight.
- the freeze-dried product may contain an excessive amount of PVA (in some cases, may contain more than the PLGA solid content) and may be used in cosmetics. It becomes an obstacle in case.
- the amount of PVA to be contained in the final PLGA composite particles is about 0.2% by weight as the PVA concentration, and at most less than 0.5% by weight, preferably less than 0.2% by weight. Preferably, one is used.
- the water is supplied together with the concentration until the film formation stops, so that the dispersibility of the PLGA particles in water is maintained.
- the addition of water is intended to prevent agglomeration by suppressing a sharp increase in the concentration of the nanoparticles. It is important to add water during the period. Therefore, after some dilution, the addition of water may be stopped.
- an aqueous solution of a sugar alcohol, a vitamin, or the like is added and freeze-dried, so that the sugar alcohol and the vitamin (a water-soluble provitamin, etc.) are mixed around the PLGA particles.
- PLGA particles can be compounded in form.
- sugar alcohol it is weak to heat, heat resistance is given to PLGA particles, PLGA composite particles can be stored stably, and redispersibility of composite particles is improved, penetrating deep into the skin become able to.
- the vitamin preparation more vitamin can be contained in the PLGA composite particles, and the effect of the vitamin preparation can be enhanced.
- the vitamin preparation may be freeze-dried to form PLGA composite particles, and then pulverized to a particle size of about 10 ⁇ m and mixed. According to this, it is possible to further increase the amount of the vitamin preparation.
- PLGA particles in which fluorescent-labeled coumarin is encapsulated instead of VC-IP are produced by a spherical crystallization method (emulsion-in-water solvent diffusion method), and human skin is produced.
- the penetration into the lip was examined.
- the permeability of a 10% solution of coumarin into human skin was examined.
- Coumarin has an excitation wavelength of 458 nm and an emission wavelength of 505 nm.
- FIG. 5 two hours after the aqueous coumarin-containing PLGA dispersion (FIG. 5 (b)) or the coumarin solution (FIG. 5 (a)) was applied to the skin on the side of a 35-year-old woman, Photographs of cross-sectional views of the epidermis after 3 hours and 4 hours are shown.
- the fluorescent dye coumarin penetrates into the dermis through the corneum (from the skin surface to 0.01 mm) and the epidermis (from the skin surface to 0.1 mm) over time, but is fluorescently stained. And the amount is small and the permeability is good.
- the coumarin-containing aqueous PLGA dispersion stained extensively to a depth of about 1 mm after 2 hours, and it can be seen that the aqueous solution quickly reached a large amount deep into the skin (more than 8 mm from the skin). After 4 hours, the area around the pores was deeply stained, suggesting that a large amount of the pores penetrated deep into the skin (Fig. 5 (b) is an enlarged view of the figure after 4 hours). 5 (c)). In other words, using one of the pores as a bypass as one of the routes of drug penetration into the deep skin area seems to enhance the penetration effect.
- a PL containing VC-IP at an encapsulation rate of 13 to 15% An aqueous dispersion of GA particles (average particle diameter 240 nm) (VC-IP concentration in the dispersion was 1%) was used, and a skin permeation test was performed by a modified Bronow diffusion chamber method.
- a VC-IP solution concentration: 1%) was used.
- Each cell lysate is separated by HPLC using a conventional method, and quantified using a fluorescent 'coulometric ECD' UV detector.
- the amount of vitamin C in the tissues of the epidermis (E) and the dermis (D) was measured.
- the PLGA used was PLGA7520 manufactured by Wako Pure Chemical Industries, and the Provitamine C (VC-IP) was manufactured by Nikko Chemical.
- the amount of vitamin C in the epidermis (E) was 0.5 hours, 2 hours, and 4 hours after, respectively.
- the amount of permeation gradually increased to about 70 ⁇ mol, about 10 nmol, and about 50 nmol.
- the amount of permeation gradually increased to about 2. lnmol, about 8 nmol, and about 14 nmol.
- VC-IP on the epidermis decreased once after 0.5 hours and then 2 hours later, and increased again after 4 hours. This may indicate that after 4 hours, the outflow of VC-IP from the PLGA particles that had penetrated deep into the skin increased, and that the outflowed VC-IP migrated from deep into the epidermis.
- the upper graph of Fig. 6 shows the ratio of reduced vitamin C (ascorbic acid) to the total vitamin C in the epidermis and dermis (Asc / t-vitamin C).
- This value indicates the ratio of effective vitamin C (reduced vitamin C) not oxidized and decomposed in the total amount of vitamin C, and indicates resistance to oxidative decomposition. In other words, it is considered that the larger this value is, the greater the medicinal effect of vitamin C, which is less likely to be oxidized and decomposed.
- reduced vitamin C remained in the dermis even after 2 hours or 4 hours in the case of PLGA particles encapsulating VC-IP. This value is good even after 4 hours of the VC-IP solution, but the permeation amount itself is low with the VC-IP solution, so the total amount of reduced vitamin C is low.
- Fig. 7 shows a value representing the reduced vitamin C amount (AscZt-vitamin C) in the dermis by multiplying the numerical value of the lower bar graph of Fig. 6 by the numerical value of the upper graph.
- the reduced form is as high as 6.7 times the value after 2 hours and almost 4 times after 4 hours compared to the VC-IP solution. It can be seen that it has vitamin C content. Therefore, it was shown that PLGA particles can permeate VC-IP in a large amount in the form of effective reduced vitamin C.
- PLGA particles can be said to exhibit the effect as a "VC-IP penetrant.”
- VC-IP Even if VC-IP is encapsulated in the PLGA particle in a reservoir form, it may be several hours after the PLGA particle has penetrated, and within a short time, the PLGA particle of the sustained-release base material may be used. VC-IP is not significantly released, and it is unlikely that VC-IP derived from this will be detected in the skin. Therefore, in the skin penetration experiments described above, it is estimated that the VC-IP force on the surface of the PLGA particles, which are monolithic nanospheres, quickly penetrated the skin and increased the amount of vitamin C deep in the skin.
- UVA ultraviolet A-wave
- UVB B-wave
- a section of the skin tissue was stained by the TUNEL method, in which a green isothiocyanate-based fluorescent dye (FITC) was selectively applied to the DNA-cut ends, and VC-IP-encapsulated PLGA particles were stained. The presence / absence of DNA breakage was observed when the coating was applied (Example) and when nothing was applied (Comparative Example).
- Fig. 8 shows the results.
- PLGA composite particles were produced according to the production method of the embodiment.
- PLGA composite particles As an example of PLGA composite particles, PLGA composite particles having the following compounding ratio (weight ratio) were obtained. PLGA: 1.00,
- PLGA during crystallization emulsion-in-water solvent diffusion method
- the redispersibility is obtained by dispersing the composite particles in purified water and measuring the particle size of the dispersed particles.
- the PLGA composite particles have a particle size of about 0.22 zm, so if the redispersibility is good, the particle size in purified water will be close to this value.
- PVA aqueous solution Any PLGA composite particles with a liquid concentration of 0.2%, 0.4%, or 0.6% can be redispersed to a particle size of 0.2-0.3 / m. It can be seen that even if is made thinner than before, it does not affect redispersibility.
- the bulk density is obtained by measuring the weight of lcc PLGA composite particles. As a method, place the PLGA composite particles in a screw bottle loosely (to the extent that they can be blended in after the sample is weighed) or in a pot (tapping 180 times), measure the height and weight, and determine the weight per lcc. Calculated. Also here, the bulk density was as low as 0.02-0. 05gZcc, and the hardness was about 0.04-0.09g / cc.
- the concentration of the used PVA aqueous solution be 0.4% or less, more preferably 0.2% or less.
- Lecithin emulsion For 1.000,
- the properties measured include ease of compatibility when mixed with emulsion, penetration into the skin when the PLGA composite particles are applied to the skin, and a mixture of 180 mg of PLGA composite particles mixed with 5 g of emulsion (hereinafter PLGA). (Referred to as latex) is applied to the skin when penetrated into the skin, and the feeling of use of PLGA latex.
- the above-mentioned lecithin emulsion is composed of water (about 80% by weight), hydrogenated lecithin (about 10% by weight), It contains renderlicol (about 10% by weight) and contains appropriate amounts of other minor ingredients such as mineral oil, glycerin, trioctanoin, isopentyldiol, cetanol, carbomer, hydroxypropylmethylcellulose, and sodium hydroxide.
- Permeability to the skin refers to an examination as to whether particles or emulsion are rapidly absorbed by the skin after being applied to the skin.
- the penetration is good at a PVA concentration of 0.4%, and very good at a PVA concentration of 0.2% or less. Penetrated.
- Eristole was used as an excipient, some permeability was observed when the PVA concentration was 0.4% or 0.2%.
- the concentration of PVA was 0.6%, both of the excipients left the particles on the skin like an aca and hardly penetrated.
- the PVA concentration should be 0.4% or less, preferably 0.2% or less. Is preferred.
- the PLGA emulsion penetrated well into the skin without depending on the excipient or PVA concentration. However, when the PVA concentration was 0.2%, penetration into the skin was particularly high. Therefore, when used as a PLGA emulsion, relatively good permeability can be obtained regardless of the PVA concentration and the excipient, but especially when the PVA concentration is 0.2% or less, the permeability is better.
- the feeling of tightness of the skin was investigated.
- the PVA concentration was 0.2%, the skin felt moderate, and when the PVA concentration was 0.4%, it felt moderately smooth. At 0.6%, the sense of tension was clear. Therefore, the PVA concentration should be 0.4% or less, more preferably 0.2, for the feeling of tightness of the skin. It has been found that it is preferable to produce at / 0 or less.
- the distillation method in the distillation step was changed in various ways (Method A-I), and the state of formation of PLGA particle aggregates after distillation, the particle size, and the redispersibility in water after freeze-drying, The presence or absence of a micron-order aggregate was observed.
- Method B is a case where, according to the embodiment, 40 g of PLGA is mixed with a solvent shown in Table 3 (PVA concentration is 0.2% by weight), and a distillation method in which water is not added at the time of distillation is employed. .
- a distillation method in which water is not added at the time of distillation is employed.
- this method B in order to obtain particles without aggregation, it was necessary to evaporate slowly at a distillation rate of 48 mlZh (25 hours).
- a long-term production hinders industrialization (see Table 5). This problem was solved by increasing the concentration of PVA to 8 g (PVA solution concentration 0.4% by weight, Method H) or 12 g (PVA solution concentration 0.6% by weight, Method I).
- nanoparticles can be successfully formed in a short time of 13 hours or 11 hours (see Table 5), such a high level and PVA concentration can be confirmed by the results of Examples 5 and 6, as shown in the results of Examples 5 and 6. This is a problem when used in cosmetics.
- C is just in the middle of the distillation time and all water is added at once, and D is the first half of the distillation time
- Method F is a method in which purified water is supplied at a constant rate of 4 mlZmin for 200 minutes after the start, and then purified water is supplied at a constant rate of 2 ml / min for 300 minutes. Upon distillation, micron particles were formed after the distillation. The particle size after freeze-drying was 250 nm, and aggregates of the order of micron were formed after freeze-drying.
- the distillation method removes the water even if it is distilled in a short time of 12 hours. After that, after freeze-drying, micron particles, liquid level film, and micron-order aggregates were hardly formed, and the particle size after freeze-drying was as good as 220 nm. Therefore, as a distillation method that does not generate micron-order particles, it is effective to perform distillation while supplying purified water at a constant rate for at least a while after the start of distillation.
- the PLGA composite particles obtained by adding an excipient and a water-soluble vitamin VC-PMG aqueous solution to the PLGA particle suspension after the distillation step, and freeze-drying the whole, have a bulk density of 0.044-0.087g. Since the powder is fluffy with / cc, high-density filling in small containers is difficult. Therefore, it is conceivable to increase the bulk density by the following method.
- PLGA composite particles were prepared.
- the bulk density of the composite particles and those obtained by adding and freeze-drying an aqueous solution of VC-PMG was measured as follows.
- the above two types of PLGA composite particles were weighed and placed in a screw bottle having a body diameter of 30 mm and an internal diameter of 27 mm so that the height of the PLGA composite particles was about 15 mm in the screw bottle. Height measurements were taken from five locations around the bottle.
- the filling volume is typically 1.5cc.
- the composite particles produced by the above method are easy to fill into a container and contain sufficient vitamin C when mixed with an emulsion having a high vitamin C concentration.
- the mixture is mixed with the emulsion contained in the emulsion container (5.5 ml).
- the amount of vitamin (VC-PMG + VC-IP) is 2.4 by weight. / 0 , it is an emulsion containing a sufficiently effective level of vitamin C. If it is necessary to further increase the amount of vitamin C, the amount of vitamin C can be further increased by increasing the amount of crushed vitamin C.
- the nanoparticle-containing composition produced by the method for producing a nanoparticle-containing composition of the present invention has excellent permeability to the skin, and contains a drug, a biocompatible polymer, and an organic solvent.
- aqueous solution By adjusting the aqueous solution to 0.5% by weight or less, the feeling of tightness when applied to the skin is suppressed and the feeling of use is good, so it can be used for cosmetics, dermatological drugs, or drugs used for transdermal application. Applicable.
- it is a nanoparticle-containing composition that is well compatible with the liquid state of emulsions and the like, and is well mixed with emulsions and the like, so that it can be used well by mixing with emulsions and the like.
- the composition containing nanoparticles since the composition containing nanoparticles has a large bulk density, It has excellent mobility and can be easily filled into small containers, and can be filled at high density.
- the above effect is one layer higher than With the concentration of polyvinyl alcohol 0.2 weight 0/0 or less.
- concentration of polyvinyl alcohol 0.2 weight 0/0 or less.
- the nanoparticle was washed by centrifugation or the like to prevent this problem.
- the method of the present invention eliminates the need for this washing. Work and time can be greatly reduced.
- the particle size of the nanoparticles is 50 nm or more and 250 nm or less, phagocytosis of cells is not received, and penetration into the deep skin through cell intervals can be expected.
- vitamins and vitamin derivatives act on the dermis to eliminate whitening effects that prevent spots and freckles, and eliminate active oxygen that causes skin aging, sunburn, and skin cancer. Since it is effective, it can be expected that a high whitening effect and UV protection effect can be obtained by incorporating it into the nanoparticles that can reach the dermis when applied to the skin and acting on the skin. In addition, since the drug contained in the nanoparticles is gradually released over a long period of time, a long-term effect can be expected.
- a nanoparticle-containing composition containing more vitamins or vitamin derivatives can be obtained.
- the complexed vitamin or vitamin derivative begins to disperse and act around immediately after use, so it has a different timing from that contained in the above nanoparticles, which gradually releases the contained drug, Act in place. Therefore, when vitamins or vitamin derivatives are included in the nanoparticles and then complexed, the complexed vitamins or vitamin derivatives show immediate effect, and those contained in the nanoparticles act slowly to release nanoparticles. If it is used as a composition and used as a whitening agent or whitening solution, it is expected to have a two-stage action of fast action and slow action.
- the compounding step is performed by freeze-drying, the compounding of the nanoparticles can be performed satisfactorily and efficiently.
- the nanoparticle-containing composition produced by the production method of the present invention is suitable for application to skin. Therefore, it is suitably used as a cosmetic or as a transdermal drug.
- the nanoparticle-containing composition including nanocomposite particles in which nanoparticles containing vitamins or vitamin derivatives and water-soluble vitamins or vitamin derivatives are complexed
- the nanoparticle-containing composition can adhere to the surface of the nanocomposite particles.
- the water-soluble vitamin or vitamin derivative that has been dissolved dissolves and exhibits a fast-acting effect, and then the vitamin or vitamin derivative contained in the nanoparticles exhibits a sustained-release effect that is gradually released. . Therefore, it becomes a nanoparticle-containing composition in which the effects of vitamins are exerted over a long period of time.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Optics & Photonics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-019882 | 2004-01-28 | ||
JP2004019882A JP4851067B2 (ja) | 2004-01-28 | 2004-01-28 | ナノ粒子含有組成物およびその製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005072707A1 true WO2005072707A1 (ja) | 2005-08-11 |
Family
ID=34823733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/000952 WO2005072707A1 (ja) | 2004-01-28 | 2005-01-26 | ナノ粒子含有組成物およびその製造方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4851067B2 (ja) |
WO (1) | WO2005072707A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006095778A1 (ja) * | 2005-03-10 | 2006-09-14 | Hosokawa Powder Technology Research Institute | 育毛成分含有ナノ粒子及びその製造方法並びにそれを用いた育毛剤 |
CN101700266A (zh) * | 2009-11-19 | 2010-05-05 | 新疆维吾尔自治区中药民族药研究所 | 雪莲纳米粒及其制备方法和应用 |
US10076501B2 (en) | 2011-12-14 | 2018-09-18 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
CN109069431A (zh) * | 2016-03-10 | 2018-12-21 | 大日本住友制药株式会社 | 包含细颗粒的组合物及其制法 |
WO2019162951A1 (en) * | 2018-02-26 | 2019-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Drug delivery systems |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5115951B2 (ja) * | 2006-03-17 | 2013-01-09 | 学校法人東京理科大学 | ナノコンポジット粒子 |
JP5071956B2 (ja) * | 2006-06-27 | 2012-11-14 | ホソカワミクロン株式会社 | 薬物封入ナノ粒子の造粒物及び造粒方法 |
JP5117004B2 (ja) * | 2006-07-21 | 2013-01-09 | ホソカワミクロン株式会社 | 固形粉末化粧料 |
JP2010275249A (ja) * | 2009-05-29 | 2010-12-09 | Hosokawa Micron Corp | 化粧料 |
JP2010275250A (ja) * | 2009-05-29 | 2010-12-09 | Hosokawa Micron Corp | 化粧料 |
JP4856752B2 (ja) * | 2009-11-30 | 2012-01-18 | ホソカワミクロン株式会社 | 薬物含有ナノ粒子の製造方法 |
WO2012101638A2 (en) * | 2011-01-24 | 2012-08-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles for cosmetic applications |
US8758826B2 (en) * | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
FR2988092B1 (fr) * | 2012-03-16 | 2014-04-25 | Centre Nat Rech Scient | Complexes de vitamine c, nanoparticules desdits complexes, procedes pour leur preparation, leurs compositions, leurs utilisations cosmetiques et procede de traitement cosmetique |
JP2018175761A (ja) * | 2017-04-21 | 2018-11-15 | ホソカワミクロン株式会社 | 毛穴分布状態の判定方法および毛穴からのナノ粒子の吸収量の判定方法 |
JP6401838B1 (ja) * | 2017-08-18 | 2018-10-10 | メディカランド株式会社 | 美白化粧料組成物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09110678A (ja) * | 1995-10-19 | 1997-04-28 | Tanabe Seiyaku Co Ltd | 被覆マイクロスフェア製剤およびその製法 |
JP2002504425A (ja) * | 1998-02-27 | 2002-02-12 | ラボラトワール・セロビオロジツク(ソシエテ・アノニム) | ミクロ粒子又はナノ粒子製造用マトリックス、前記粒子の製造方法及び得られる粒子 |
JP2003275281A (ja) * | 2002-03-20 | 2003-09-30 | Hosokawa Micron Corp | 薬物含有複合粒子の製造方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2608942B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
FR2610626B1 (fr) * | 1987-02-09 | 1989-05-19 | Oreal | Nouveau systeme anti-oxydant a base d'un ester d'ascorbyle stabilise, contenant en association au moins un agent complexant et au moins un thiol, et compositions contenant un tel systeme anti-oxydant |
FR2659554B1 (fr) * | 1990-03-16 | 1994-09-30 | Oreal | Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant. |
JP3226300B2 (ja) * | 1990-07-18 | 2001-11-05 | エーザイ株式会社 | プロナノスフィア及びその製造方法 |
JPH115725A (ja) * | 1997-06-13 | 1999-01-12 | Shiseido Co Ltd | 皮膚外用剤 |
DE69841984D1 (de) * | 1997-09-05 | 2010-12-16 | Maruho K K | Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen |
CA2731995C (en) * | 1998-09-01 | 2013-05-28 | Merrion Research Iii Limited | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
CN1294896C (zh) * | 2000-12-28 | 2007-01-17 | 株式会社资生堂 | 干燥引起皮肤损伤的抑制剂或修复剂及其评价方法 |
JP4091825B2 (ja) * | 2002-02-05 | 2008-05-28 | 株式会社コーセー | 皮膚外用剤 |
-
2004
- 2004-01-28 JP JP2004019882A patent/JP4851067B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-26 WO PCT/JP2005/000952 patent/WO2005072707A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09110678A (ja) * | 1995-10-19 | 1997-04-28 | Tanabe Seiyaku Co Ltd | 被覆マイクロスフェア製剤およびその製法 |
JP2002504425A (ja) * | 1998-02-27 | 2002-02-12 | ラボラトワール・セロビオロジツク(ソシエテ・アノニム) | ミクロ粒子又はナノ粒子製造用マトリックス、前記粒子の製造方法及び得られる粒子 |
JP2003275281A (ja) * | 2002-03-20 | 2003-09-30 | Hosokawa Micron Corp | 薬物含有複合粒子の製造方法 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006095778A1 (ja) * | 2005-03-10 | 2006-09-14 | Hosokawa Powder Technology Research Institute | 育毛成分含有ナノ粒子及びその製造方法並びにそれを用いた育毛剤 |
CN101700266A (zh) * | 2009-11-19 | 2010-05-05 | 新疆维吾尔自治区中药民族药研究所 | 雪莲纳米粒及其制备方法和应用 |
CN101700266B (zh) * | 2009-11-19 | 2013-12-04 | 国药集团新疆制药有限公司 | 雪莲纳米粒及其制备方法和应用 |
US10076501B2 (en) | 2011-12-14 | 2018-09-18 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
US10555912B2 (en) | 2011-12-14 | 2020-02-11 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
CN109069431A (zh) * | 2016-03-10 | 2018-12-21 | 大日本住友制药株式会社 | 包含细颗粒的组合物及其制法 |
EP3427724A4 (en) * | 2016-03-10 | 2019-11-13 | Sumitomo Dainippon Pharma Co., Ltd. | COMPOSITION CONTAINING FINE PARTICLES, AND PRODUCTION METHOD THEREOF |
US11147811B2 (en) | 2016-03-10 | 2021-10-19 | Sumitomo Dainippon Pharma Co., Ltd. | Composition comprising fine particle and process thereof |
CN109069431B (zh) * | 2016-03-10 | 2022-03-01 | 大日本住友制药株式会社 | 包含细颗粒的组合物及其制法 |
WO2019162951A1 (en) * | 2018-02-26 | 2019-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Drug delivery systems |
Also Published As
Publication number | Publication date |
---|---|
JP2005213170A (ja) | 2005-08-11 |
JP4851067B2 (ja) | 2012-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005072707A1 (ja) | ナノ粒子含有組成物およびその製造方法 | |
Garg et al. | Ethosomes and transfersomes: Principles, perspectives and practices | |
Uchechi et al. | Nanoparticles for dermal and transdermal drug delivery | |
Müller-Goymann | Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration | |
KR100394770B1 (ko) | 토코페롤 유도체를 이용하여 나노유화입자를 안정화시키는방법 및 나노유화입자를 함유하는 피부 외용제 조성물 | |
KR100810164B1 (ko) | 이데베논 나노캡슐을 함유하는 주름개선 화장료 조성물 및이의 제조방법 | |
Aggarwal et al. | Preparation and in vivo evaluation of solid lipid nanoparticles of griseofulvin for dermal use | |
Rigano et al. | Nanobiomaterials in galenic formulations and cosmetics | |
JP5548362B2 (ja) | 油溶性活性成分を捕集した陽イオン性高分子ナノカプセル及びこれを含有する化粧料組成物 | |
KR100785484B1 (ko) | 고농도의 이데베논을 나노캡슐화한 기제 조성물, 이의제조방법 및 이를 함유한 화장료 | |
JPWO2006118245A1 (ja) | 皮膚再生促進剤 | |
F Antunes et al. | Nanosystems for skin delivery: from drugs to cosmetics | |
JP2009173610A (ja) | タンパク質ナノ粒子 | |
CN107106421B (zh) | 表皮生长因子和脂质体的混合型多层纳米结构及其制造方法 | |
Singh et al. | Niosomes-a novel tool for anti-ageing cosmeceuticals | |
JP6875289B2 (ja) | 難溶性薬物伝達用の溶解性マイクロニドル | |
Yücel et al. | Ethosomal (−)-epigallocatechin-3-gallate as a novel approach to enhance antioxidant, anti-collagenase and anti-elastase effects | |
JP2009249370A (ja) | タンパク質ナノ粒子 | |
Manickam et al. | Drug/vehicle impacts and formulation centered stratagems for enhanced transdermal drug permeation, controlled release and safety: unparalleled past and recent innovations-an overview | |
KR101032623B1 (ko) | pH 반응형 공중합체와 인지질로 구성된 이중 캡슐 및 이를 함유하는 화장료 조성물 | |
Dominguez et al. | Nanotechnology to enhance transdermal delivery of hydrophilic humectants for improved skin care: a model for therapeutic applications | |
JP2008179551A (ja) | 経皮吸収製剤 | |
JP3834563B2 (ja) | アルブチンを利用した安定なナノ乳化粒子の製造方法及びナノ乳化粒子を含有する化粧料組成物 | |
Bera et al. | Transfersomes and Ethosomes: Nano Carriers and their Clinical Potential in Transdermal Drug Delivery System | |
RU2481822C1 (ru) | Микроэмульсионные композиции для создания трансдермальных и трансмукозальных форм фармацевтических средств и косметических препаратов и способ их получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |